Cell mediated immune status in malignancy--pretherapy and post-therapy assessment

Area of Science:

• Immunology
• Oncology

Background:

• T-cell activity and population are crucial indicators in cancer patients.
• Assessing immune status before and after treatment is vital for prognosis.

Purpose of the Study:

• To evaluate T-cell activity and population in various malignancies.
• To determine the impact of therapy on T-cell status and clinical outcomes.

Main Methods:

• Studied 28 malignancy cases (squamous cell carcinoma, breast duct carcinoma, non-Hodgkin's lymphoma).
• Assessed Mantoux test (MT) and T-cell population (<40% vs. >40%) pre- and post-therapy.
• Compared patient data with healthy controls (MT positive, T-cell >40%).

Main Results:

• Pre-therapy: 20% of squamous cell carcinomas, 28.6% of breast cancers, and 50% of NHL cases had MT-negative results and T-cell counts <40%.
• Post-therapy: Significant positive conversion in MT and T-cell counts (>40%) observed in 66.66% of squamous cell carcinomas, 100% of breast cancers, and 33.33% of NHL.
• Healthy controls consistently showed MT-positive results and T-cell counts >40%.

Conclusions:

• Reduced T-cell activity (MT-negative, T-cell <40%) is common in various cancers.
• Successful cancer therapy can lead to immune recovery, evidenced by improved T-cell function and population.
• T-cell status assessment may serve as a biomarker for treatment response in oncology.